Clint Brauer grew up on his family's Kansas farm. His dad sprayed the same chemicals every American farmer sprays. Years later: Parkinson's. Clint walked away from a tech career to build a different way. Today his company, Greenfield Robotics, runs a patented fleet of autonomous bots that slice weeds with centimeter precision, day or night, herbicide-free. 

Greenfield is now opening shares to everyday investors under Reg A+. Reserve during Test the Waters and you lock in a 5% bonus that can grow to 20% the week the round goes live. The US has 250 million acres at stake.

Get Bonus Shares

_{Greenfield Robotics is Testing The Waters under tier 2 of Regulation A. No money or other consideration is being solicited, and if sent in response will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.}

Every week, we cut through the noise and surface opportunities that institutions are already eyeing, but with strategies tailored for retail traders. Today's setup? A beaten-down e-commerce name the market prices as a slowing pet food shop, while it quietly builds a vet clinic network that changes what it can sell you. Having just taken my dog, Gruff, to the vet, I can assure you those are lucrative, which also helped inspire the trade idea today.

We’ll cover:

Chewy (CHWY) trades about 47% below its 52-week high of $43.50. The market's verdict is simple: online pet retail has matured, growth has slowed to single digits, and management cut guidance in June. That is the stock you can see.

The stock you cannot see is being assembled underneath it. A customer who buys kibble leaves the moment someone undercuts you by 5%. A customer whose vet works in your clinic and whose prescriptions run through your pharmacy is a different animal. Nobody comparison-shops a vaccination schedule.

Behind the scenes:

🏥 The clinic count is inflecting, not creeping. Modern Animal takes Chewy Vet Care from 18 locations to 47 in one step, with roughly 60 expected by the end of fiscal 2026.

💵 The revenue is contracted, not hypothetical. It adds over $125 million of annualized run-rate revenue, at clinics doing more than twice the industry-average revenue per location.

🔁 The base is stickier than the growth rate suggests. Autoship grew over 10% in Q1 and is now 84.4% of net sales. That is a subscription business wearing a retailer's clothing.

📈 Profitability is inflecting faster than revenue. Q1 adjusted EBITDA margin hit a record 7.5%, up 130 basis points, on net sales of $3.36 billion (+7.7%).

🩺 This is a share shift, not a side business. Every clinic visit pulls pharmacy, food and insurance onto Chewy's platform.

The honest bear case: on June 10 Chewy cut full-year organic revenue guidance by roughly 215 basis points, saying the pet environment had become incrementally more challenged. The acquired clinics are expected to be EBITDA-dollar neutral this year, with contribution starting in 2027. You are paying now for profit that lands next year.

Sentiment is washed out, and that is the point. The stock sits 47% below its high with roughly 27.7 million shares sold short, yet the 25 analysts covering it carry a Buy consensus and an average target near $31, about 34% above the price. That gap measures the disagreement packed into this name.

Underneath the noise, the metrics that matter keep building: 21.5 million active customers, up 3.6% in Q1. Revenue growth of 7.7% is the number the market hates. Margin expansion of 130 basis points is the number it is ignoring. And look at what management did in June: they cut the revenue guide to $13.40 to $13.55 billion and left the 6.6% to 6.8% adjusted EBITDA margin guide untouched. They took down the top line and defended the profit.

Chewy has spent the summer building a base off the $17.40 low, and the shape is constructive without being extended.

✅ Trading above the 50-day moving average near $20.97, which has turned higher

✅ Still below the 200-day moving average near $26.46, so this is a recovery, not a completed trend

✅ Holding well above the $17.40 52-week low

✅ Implied volatility near 66% sits well above realized volatility near 42%

Key levels: support $20.97 (50-day) then $19.50; resistance $25 then the 200-day near $26.46; targets $27 initial, $31 intermediate.

The setup: price sits above a rising short-term average and below a falling long-term one, the classic spot for a base that either fails back to the lows or resolves up into the gap. September earnings likely decides which.

Who should take this: investors willing to hold through a September print, and options traders who want defined risk on a contrarian call. Who should not: anyone needing this to work inside 30 days.

Recommendation: Buy $CHWY at $23.00 or better. It jumped about 4% on August 18 with no company-specific news behind the move, so work a limit and do not chase strength. Add near $21 on a retest of the 50-day. Risk line is a decisive close below $19.50. First target $27, then $31.

Why a spread and not calls: implied volatility is 66% against realized near 42%, in the 76th percentile of its own year. You are being offered rich premium, so you sell the expensive wing rather than pay for it outright.

Why January. I repriced the same $22.50 / $30 spread across all three expiries at the close: November 20 at $2.55 (2.7 cents per day), January 15 at $2.90 (1.9 cents), March 19 at $3.10 (1.5 cents). March is cheapest per day, but Q4 lands at or after that expiry, so the extra days buy no catalyst. November is cheapest outright but expires before the December quarter is reported, forcing the thesis onto one print. January is the shortest expiry covering both.

🛡️ The Options Play (one trade, defined risk):

📉 Risk-Reward Breakdown - Jan 2027 $22.50 / $30 Call Spread

💰 Payoff Table (per spread, $290 debit)

How it works: you pay $290 for Chewy's move from $22.50 up to $30 between now and January. Above $30 you stop participating, which is the price of the discount. Below $22.50 you lose the $290 and nothing more.

(Quotes as of the August 18 close. The bid/ask midpoint on this spread sits near $2.60, so work a limit rather than paying the full offer. Verify with live brokerage prices before entering.)

Use $19.50 as your hard risk line on the shares. A decisive close below it means the base failed and the guidance cut was the signal, not the noise. Size the stock so a move there costs no more than 1% to 2% of your account. The spread is already defined risk, so size it by the premium you can lose.

Keep your eyes on:

$CHWY is a story about what a company is allowed to sell you. Selling dog food is a price war. Selling veterinary care and the prescriptions that follow is a relationship, and relationships do not churn over a 5% coupon.

The market is pricing the guidance cut, which is real, and ignoring the clinic build-out, which is also real and much harder to reverse. Going from 18 locations to roughly 60 inside one fiscal year is not a pilot program, it is a decision.

The timing is not clean. Management guided lower in June, and this trade bets the back half proves them conservative. That is why the options leg is a defined-risk spread, not a naked call.

✅ Buy $CHWY at $23.00 or better
💸 Buy the Jan 15, 2027 $22.50 / $30.00 call spread for a $2.90 net debit

We'll be watching this one closely.

Want more trade ideas like this - plus weekly options plays and breakdowns?

👉 Join the Paid Resilient Trader Newsletter

For more in-depth trading strategies and market insights, upgrade to the paid version of our newsletter.

Our paid newsletter gives you:

Stay Liquid, my friends
- The Resilient Trader